Loading...
XNYS
A
Market cap34bUSD
Jun 10, Last price  
120.52USD
1D
3.24%
1Q
0.56%
Jan 2017
164.53%
Name

Agilent Technologies Inc

Chart & Performance

D1W1MN
P/E
26.56
P/S
5.26
EPS
4.54
Div Yield, %
0.59%
Shrs. gr., 5y
-1.76%
Rev. gr., 5y
4.75%
Revenues
6.51b
-4.73%
5,139,000,0004,973,000,0005,420,000,0005,774,000,0004,481,000,0005,444,000,0006,615,000,0006,858,000,0006,782,000,0006,981,000,0004,038,000,0004,202,000,0004,472,000,0004,914,000,0005,163,000,0005,339,000,0006,319,000,0006,848,000,0006,833,000,0006,510,000,000
Net income
1.29b
+3.95%
327,000,0003,307,000,000638,000,000693,000,000-31,000,000624,000,0001,012,000,0001,153,000,000724,000,000497,000,000398,000,000460,000,000684,000,000316,000,0001,071,000,000719,000,0001,210,000,0001,254,000,0001,240,000,0001,289,000,000
CFO
1.75b
-1.19%
899,000,000634,000,000969,000,000756,000,000408,000,000712,000,0001,260,000,0001,228,000,0001,152,000,000713,000,000491,000,000793,000,000889,000,0001,087,000,0001,021,000,000921,000,0001,485,000,0001,312,000,0001,772,000,0001,751,000,000
Dividend
Oct 01, 20240.236 USD/sh
Earnings
Aug 19, 2025

Profile

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
URL
https://www.agilent.com/
IPO date
Nov 18, 1999
Employees
18,300
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑102023‑102022‑102021‑102020‑102019‑102018‑102017‑102016‑102015‑10
Income
Revenues
6,510,000
-4.73%
6,833,000
-0.22%
6,848,000
8.37%
Cost of revenue
3,454,000
3,849,000
3,593,000
Unusual Expense (Income)
NOPBT
3,056,000
2,984,000
3,255,000
NOPBT Margin
46.94%
43.67%
47.53%
Operating Taxes
232,000
99,000
250,000
Tax Rate
7.59%
3.32%
7.68%
NOPAT
2,824,000
2,885,000
3,005,000
Net income
1,289,000
3.95%
1,240,000
-1.12%
1,254,000
3.64%
Dividends
(274,000)
(265,000)
(250,000)
Dividend yield
0.72%
0.87%
0.60%
Proceeds from repurchase of equity
(1,150,000)
(575,000)
(1,081,000)
BB yield
3.03%
1.88%
2.60%
Debt
Debt current
45,000
36,000
Long-term debt
3,345,000
3,017,000
2,733,000
Deferred revenue
Other long-term liabilities
708,000
462,000
633,000
Net debt
1,886,000
1,263,000
1,521,000
Cash flow
Cash from operating activities
1,751,000
1,772,000
1,312,000
CAPEX
(378,000)
(298,000)
(291,000)
Cash from investing activities
(1,258,000)
(310,000)
(338,000)
Cash from financing activities
(752,000)
(930,000)
(1,372,000)
FCF
2,756,000
2,395,000
2,466,000
Balance
Cash
1,329,000
1,590,000
1,053,000
Long term investments
175,000
164,000
195,000
Excess cash
1,178,500
1,412,350
905,600
Stockholders' equity
448,000
458,000
(20,000)
Invested Capital
9,548,000
8,702,000
8,727,000
ROIC
30.95%
33.11%
34.04%
ROCE
30.57%
32.58%
37.38%
EV
Common stock shares outstanding
291,000
296,000
300,000
Price
130.31
26.06%
103.37
-25.28%
138.35
-12.15%
Market cap
37,920,210
23.93%
30,597,520
-26.28%
41,505,000
-14.16%
EV
39,806,210
31,860,520
43,026,000
EBITDA
3,313,000
3,255,000
3,572,000
EV/EBITDA
12.02
9.79
12.05
Interest
96,000
95,000
84,000
Interest/NOPBT
3.14%
3.18%
2.58%